Table 1

Clinical characteristics of the patients with primary SS and non-SS control groups

Controls (n=4)pSS HM 450 K (n=8)pSS bisulfite sequencing (n=8)
Age, years, mean (range)49 (38–66)54 (24–74)59 (39–76)
Dry mouth, n (%)3/4 (75)6/8 (75)8/8 (100)
ESSDAI (≥5)5/8 (62.5%)
Autoantibodies
 ANA (HEp-2 cells), n (%)08/8 (100)7/8 (87.5)
 Anti-SSA/Ro, n (%)05/8 (62.5)4/8 (50
 Anti-SSB/La, n (%)03/8 (37.5)2/8 (25)
 RF, n (%)08/8 (100)3/8 (37.5)
Biopsies
 Focus score*, mean (range)<15.2 (1–9)4.1 (1–8)
 Chisholm-Mason grade≥III, n (%)<15/8 (62.5)3/8 (37.5)
Treatment
 Hydroxychloroquine, n (%)04/8 (50)3/8 (37.5)
  • *The focus score is the number of mononuclear cell infiltrates containing at least 50 inflammatory cells (lymphocytic foci) in a 4 mm2 of glandular tissue section.

  • ANA, antinuclear antibodies; ESSDAI, EULAR Sjögren's syndrome disease activity index; HEp-2, Human Epithelioma 2 cell line; HM, HumanMethylation; no., number; pSS, primary Sjögren's syndrome; RF, rheumatoid factor; SS, Sjögren's syndrome; SSA, sicca syndrome A; SSB, sicca syndrome B.